Cantor Fitzgerald, L. P. Unicycive Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $4.65 Billion
- Q1 2025
A detailed history of Cantor Fitzgerald, L. P. transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 32,971 shares of UNCY stock, worth $145,731. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,971Holding current value
$145,731% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding UNCY
# of Institutions
30Shares Held
59.9MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA11.4MShares$50.3 Million1.76% of portfolio
-
Great Point Partners LLC Greenwich, CT11MShares$48.5 Million3.87% of portfolio
-
Octagon Capital Advisors LP New York, NY10MShares$44.2 Million1.9% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT9.39MShares$41.5 Million0.24% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$22.4 Million0.56% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $66.5M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...